Clinical Trials Browser

Phase 1/2 × Inflammatory Breast Neoplasms × grapiprant × Clear all

NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Inflammatory Breast Neoplasms